Essilor : Procedures for Requesting or Viewing Proxy Information for the Combined Ordinary and Extraordinary Annual Meeting on

  Essilor : Procedures for Requesting or Viewing Proxy Information for the
  Combined Ordinary and Extraordinary Annual Meeting on May 7, 2014

Business Wire

CHARENTON-LE-PONT, France -- April 3, 2014

Regulatory News:

Essilor (Paris:EI):

Shareholders are advised that the Combined Ordinary and Extraordinary Annual
Meeting will be held on Wednesday, May 7, 2014 at 10:30 am CEST at Palais des
Congrès de Paris, 2 place de la Porte Maillot, 75017 Paris, France.

The preliminary notice of meeting, published in the Bulletin des Annonces
Légales Obligatoires on March 28, 2014, contains information on the agenda,
the proposed resolutions and the procedures for attending and voting.

Proxy information may be viewed in the Investors section of the Essilor
corporate website at http://www.essilor.com: “Individual Shareholder
Information / Annual Shareholders’ Meetings”.

As provided for in articles R.225-88 and R.225-89 of the French Commercial
Code, any shareholder may consult the proxy documents and information, as
described in article R.225-83 of the French Commercial Code, at Company
headquarters (147 rue de Paris, 94220 Charenton-le-Pont, France) or request
that such documents be sent to him or her, by writing to Société Générale,
Service des Assemblées, 32 rue du Champ de Tir, CS 30812, 44308 Nantes Cedex
03, France.

About Essilor
The world’s leading ophthalmic optics company, Essilor designs, manufactures
and markets a wide range of lenses to improve and protect eyesight. Its
corporate mission is to improve lives by improving sight. To support this
mission, the Company allocates more than €150 million to research and
innovation every year, in a commitment to continuously bring new, more
effective products to market. Essilor’s flagship brands are Varilux^®,
Crizal^®, Transitions^®, Definity^®, Xperio^®, Optifog^TM, Foster Grant^®,
Bolon^® and Costa^®. It also develops and markets equipment, instruments and
services for eyecare professionals.
Essilor reported consolidated revenue of over €5 billion in 2013 and employs
more than 55,000 people. It distributes its products in more than 100
countries with 28 plants, more than 450 prescription laboratories and edging
facilities, as well as several research and development centers around the
world.
For more information, please visit www.essilor.com.
The Essilor share trades on the NYSE Euronext Paris market and is included in
the Euro Stoxx 50 and CAC 40 indices.
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Contact:

Essilor
Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16
 
Press spacebar to pause and continue. Press esc to stop.